Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ · Healthcare
Aurinia Pharmaceuticals Inc. EBITDA 2018–2025
Aurinia Pharmaceuticals Inc. annual/quarterly ebitda history and growth rate from 2020 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Aurinia Pharmaceuticals Inc. ebitda for the quarter ending March 31, 2026 was 46.2 M, a 73.16% increase year-over-year.
- Aurinia Pharmaceuticals Inc. annual ebitda for 2025 was 124.4 M, a 742.68% increase from 2024.
- Aurinia Pharmaceuticals Inc. annual ebitda for 2024 was 14.8 M, a 118.44% decrease from 2023.
- Aurinia Pharmaceuticals Inc. annual ebitda for 2023 was -80.0 M, a 26.41% decrease from 2022.
- Aurinia Pharmaceuticals Inc. annual ebitda for 2022 was -108.8 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Aurinia Pharmaceuticals Inc. EBITDA — FAQ
Aurinia Pharmaceuticals Inc. (AUPH) ebitda over the last 8 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see AUPH's ebitda history?
The chart and table above show Aurinia Pharmaceuticals Inc.'s ebitda by year and by quarter, including the growth rate.